Cargando…

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some mutations create a non-functional protein, whereas others confer oncogenic activity, which we term ‘oncomorphic’. Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to determin...

Descripción completa

Detalles Bibliográficos
Autores principales:	BRACHOVA, PAVLA, MUETING, SAMUEL R., CARLSON, MATTHEW J., GOODHEART, MICHAEL J., BUTTON, ANNA M., MOTT, SARAH L., DAI, DONGHAI, THIEL, KRISTINA W., DEVOR, ERIC J., LESLIE, KIMBERLY K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277253/ https://www.ncbi.nlm.nih.gov/pubmed/25385265 http://dx.doi.org/10.3892/ijo.2014.2747

Ejemplares similares

Oncomorphic TP53 Mutations in Gynecologic Cancers Lose the Normal Protein:Protein Interactions with the microRNA Microprocessing Complex
por: Brachova, Pavla, et al.
Publicado: (2014)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Kupryjanczyk, Jolanta, et al.
Publicado: (2008)

p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers
por: Devor, Eric J., et al.
Publicado: (2017)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019)

Creation and validation of models to predict response to primary treatment in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2021)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2022)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment
por: Meng, Xiangbing, et al.
Publicado: (2011)

miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer()()
por: Hovey, Adriann M., et al.
Publicado: (2015)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2021)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer
por: Wang, Wei, et al.
Publicado: (2019)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
por: Chien, Jeremy, et al.
Publicado: (2015)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells
por: Lorenzon, Ilaria, et al.
Publicado: (2019)

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
por: Lankester, K J, et al.
Publicado: (2005)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6bhdbupkiq4n3c87jv28chfb9o